Home›Allergy & Immunology› Necroptosis emerges as pathogenic hub in asthma, linking type 2 inflammation and steroid resistance
Necroptosis emerges as pathogenic hub in asthma, linking type 2 inflammation and steroid resistanceNecroptosis may drive severe inflammation in asthma cases
Frontiers in MedicinePublished June 23, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret necroptosis as a potential asthma driver, but await human validation before clinical application.
This systematic review synthesizes preclinical evidence to propose necroptosis—a programmed cell death pathway driven by RIPK1, RIPK3, and MLKL—as a central pathogenic mechanism in asthma. The authors argue that necroptosis acts as a hub that initiates type 2 inflammation via damage-associated molecular patterns (DAMPs), establishes a neutrophilic, steroid-refractory inflammatory milieu, and contributes to airway remodeling. No pooled effect sizes are reported, as the evidence is qualitative and derived largely from preclinical models.
The review identifies gaps in translating these findings to human asthma, noting that direct clinical evidence is lacking. Limitations include the reliance on animal and in vitro studies, which may not fully recapitulate human disease. The authors do not report safety data, funding sources, or conflicts of interest.
Practice relevance is speculative: the review suggests potential for patient stratification using necroptosis biomarkers and development of novel pharmacological inhibitors targeting this pathway. However, until human studies confirm these mechanisms, clinical application remains distant. Clinicians should interpret these findings as hypothesis-generating rather than practice-changing.
How this fits prior evidence
This systematic review extends prior coverage of asthma pathogenesis by proposing necroptosis as a unifying mechanism. Prior items focused on specific interventions (omalizumab, bacterial lysates, IL1R1 antagonists) or genetic risk (polygenic risk scores for IL-1 signaling). The current review addresses a gap by suggesting a common upstream pathway that could explain both type 2 inflammation and steroid resistance, potentially linking to the IL-1 signaling validated by polygenic risk scores. However, unlike the prior items that provided clinical trial data, this review remains preclinical, so its clinical relevance is less immediate.
Living with asthma can be incredibly frustrating, especially when standard treatments like corticosteroids stop working. Researchers are looking into why some cases become resistant to these common medications. They have identified a specific type of cell death called necroptosis as a potential culprit behind this persistent inflammation.
This process involves proteins like RIPK1 and MLKL that can trigger a cycle of severe inflammation. When this happens, it can lead to a 'steroid-refractory' environment where the body continues to react even when medicine is present. This pathway may also contribute to long-term changes in the airways, known as remodeling.
While these findings are promising for developing new ways to identify and treat specific types of asthma, it is important to note that much of this evidence currently comes from laboratory models rather than human clinical trials. Future research will need to confirm how these mechanisms work in people before new treatments can be developed.
What this means for you:
Necroptosis may drive steroid-resistant inflammation and airway changes in some asthma cases.
Common questions
What is necroptosis and how does it affect asthma?
Necroptosis is a specific type of cell death involving proteins like RIPK1, RIPK3, and MLKL. In the context of asthma, it is thought to act as a hub that triggers inflammation and contributes to airway remodeling. It may specifically lead to a steroid-refractory milieu, where the body's inflammation does not respond well to standard corticosteroid treatments.
Can this research help treat asthma that doesn't respond to steroids?
The findings suggest potential for better patient stratification using necroptosis biomarkers. By identifying patients whose condition is driven by this specific pathway, doctors may eventually be able to use new pharmacological inhibitors to target the underlying cause of steroid-resistant inflammation.
Is this finding ready to be used in clinical practice?
While the research identifies necroptosis as a potential driver of asthma symptoms, much of the current evidence is derived from preclinical models. Because these findings are not yet based on large-scale human trials, you should consult your doctor regarding your specific treatment plan and any new medical developments.
Asthma is a heterogeneous chronic airway disease traditionally framed within the context of dysregulated adaptive T helper 2 (Th2) immunity. However, this paradigm insufficiently explains disease chronicity, structural remodeling, and the limited efficacy of corticosteroids in specific endotypes. The discovery of necroptosis, a regulated form of lytic cell death governed by receptor-interacting protein kinase 1 and 3 (RIPK1/RIPK3) and mixed-lineage kinase domain-like protein (MLKL), introduces a transformative perspective. This review posits that necroptosis is not a passive endpoint but an active pathogenic hub in asthma. We systematically dissect how asthma-relevant triggers (allergens, viruses, pollutants) activate necroptosis in a cell-specific manner. We detail the consequences: damage-associated molecular pattern (DAMP)-driven initiation and amplification of type 2 inflammation via epithelial death, the establishment of a neutrophilic, steroid-refractory milieu through immune cell necroptosis, and direct contributions to airway remodeling. Furthermore, we discuss the interconnectedness of necroptosis with pyroptosis and apoptosis within the PANoptosis framework, and acknowledge the limitations of current evidence derived largely from preclinical models. Finally, we explore therapeutic implications, advocating for patient stratification using necroptosis biomarkers and evaluating novel pharmacological inhibitors. By integrating necroptosis into the asthma pathophysiological network, this review provides a unified mechanistic framework that bridges initial insult to sustained inflammation and tissue remodeling, unveiling novel avenues for disease-modifying therapies.
